TWST — Twist Bioscience Income Statement
0.000.00%
Last trade - 00:00
- $2.00bn
- $1.69bn
- $245.11m
- 72
- 18
- 80
- 57
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 54.4 | 90.1 | 132 | 204 | 245 |
Cost of Revenue | |||||
Gross Profit | 6.96 | 28.7 | 51.7 | 84.2 | 89.7 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 163 | 230 | 285 | 434 | 462 |
Operating Profit | -109 | -140 | -153 | -230 | -217 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -107 | -140 | -154 | -228 | -203 |
Provision for Income Taxes | |||||
Net Income After Taxes | -108 | -140 | -152 | -218 | -205 |
Net Income Before Extraordinary Items | |||||
Net Income | -108 | -140 | -152 | -218 | -205 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -108 | -140 | -152 | -218 | -205 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -3.92 | -3.2 | -3.15 | -4.1 | -3.41 |